Treatment advances for CLL, the most common leukemia
Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of leukemia in adults. According to the American Cancer Society, more than 20,000 new cases of the leukemia will be diagnosed in the U.S. this year, and nearly 4,000 people will die from the disease.
Built upon the long-standing expertise of clinicians and researchers at MD Anderson, the CLL Moon Shot™ is working...
Analysis indicates blood cancer drugs are overpriced
The costs associated with cancer drug prices have risen dramatically over the past fifteen years, which concerns many top oncologists. In...
Sign of Epstein-Barr Virus found in chronic lymphocytic leukemia
A molecule expressed by the Epstein-Barr virus is found in the B cells, bone marrow and plasma of patients with chronic lymphocytic leukemia...
Experimental gene therapy successful in certain lymphomas, leukemia
Study results of CD19-directed chimeric antigen receptor (CAR) therapy using the Sleeping Beauty non-viral transduction system to modify T cells have demonstrated further promise in patients with advanced hematologic malignancies.
Patients who had acute lymphocytic leukemia (ALL), non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) were part of clinical trials at MD Anderson Cancer Center that used the Sleeping Beauty...
Fast-tracking immunotherapy to fight leukemia
To speed the development of new cancer drugs, Bristol-Myers Squibb and MD Anderson are teaming up to conduct clinical trials of several new...